<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180397</url>
  </required_header>
  <id_info>
    <org_study_id>GODIF</org_study_id>
    <nct_id>NCT04180397</nct_id>
  </id_info>
  <brief_title>Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.</brief_title>
  <acronym>GODIF</acronym>
  <official_title>Goal Directed Fluid Removal in Intensive Care Patients With Fluid Overload - A Randomized, Blinded, Placebo-controlled Trial (GODIF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten H. Bestle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Research in Intensive Care (CRIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordsjaellands Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefits and harms of goal directed fluid removal with furosemide&#xD;
      versus placebo in critical ill adult patients with fluid overload in the intensive care unit.&#xD;
      Half of the patients will receive furosemide and the other half placebo. The treatment will&#xD;
      continue until the excess fluid is excreted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluid overload is a common and serious complication in patients admitted to the intensive&#xD;
      care unit (ICU). A core element of therapy in the ICU is resuscitation with crystalloid&#xD;
      solutions. In many cases fluid accumulate, and patients become fluid overloaded. Several&#xD;
      observational studies indicate a detrimental effect of fluid overload in different clinical&#xD;
      settings, including patients with acute kidney injury. It is unknown whether this association&#xD;
      is causal or if the increased tendency to accumulate fluid is a marker of disease severity&#xD;
      and thereby a higher risk of death. The investigators want to investigate this in critical&#xD;
      ill patients with fluid overload of 5% or more by randomizing them to furosemide (diuretics)&#xD;
      or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">November 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Days alive and out of hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and life support</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Days alive without life support without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality 1 year</measure>
    <time_frame>one year after randomization</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events and reactions</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with one or more serious adverse events and serious adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Measured using the European quality of Life 5D-5L questionnaire (5D-5L is the full name of the questionnaire). Index value of 1 represents full health and dead = 0. These value sets reflect the preferences of the general population. The European quality of life visual analogue scale is a self-reported assessment of the participant's health status. Scores on 100 = the best health you can imagine and 0 = the worst health you can imagine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Cognitive function assessed by the Montreal Cognitive Assessment score. Using the mini test for telephone interview. The test and scoring system will soon be published from Montreal Cognitive Assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide 10 mg/ml for injection/infusion</description>
    <arm_group_label>Furosemide</arm_group_label>
    <other_name>Furix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>Isotonic saline used as placebo (injection/infusion)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: ALL below must be met.&#xD;
&#xD;
          -  Acute admission to the intensive care unit.&#xD;
&#xD;
          -  Age ≥ 18 years of age&#xD;
&#xD;
          -  Fluid overload defined as a positive cumulative fluid balance (according to the daily&#xD;
             fluid charts) corresponding ≥ 5% of ideal body weight (calculated as: 22 x (height in&#xD;
             meters)^2). If possible, all fluids administered before admission to the intensive&#xD;
             care unit are to be included in the calculation of cumulative fluid balance.&#xD;
&#xD;
          -  Clinical stable defined as MAP &gt; 50 mmHg and maximum infusion of 20&#xD;
             microgram/kg/minute of noradrenaline and lactate &lt; 4.0 mmol/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to furosemide or sulphonamides.&#xD;
&#xD;
          -  Known pre-hospitalization advanced chronic kidney disease (eGFR &lt; 30 mL/minute/1.73&#xD;
             m^2 or chronic RRT).&#xD;
&#xD;
          -  Ongoing renal replacement therapy.&#xD;
&#xD;
          -  Anuria &gt; 6 hours.&#xD;
&#xD;
          -  Rhabdomyolysis with indication for forced diuresis&#xD;
&#xD;
          -  Ongoing life-threatening bleeding as these patients need specific fluid/blood product&#xD;
             strategies.&#xD;
&#xD;
          -  Acute burn injury of more than 10% of the body surface area as these patients need a&#xD;
             specific fluid strategy.&#xD;
&#xD;
          -  Severe dysnatremia (p-Na &lt; 120 or &gt; 155 mmol/L) as these patients need a specific&#xD;
             fluid strategy.&#xD;
&#xD;
          -  Severe hepatic failure as per the clinical team.&#xD;
&#xD;
          -  Patients undergoing forced treatment.&#xD;
&#xD;
          -  Fertile women (women &lt; 50 years) with positive urine human chorionic gonadotropin&#xD;
             (hCG) or plasma-hCG.&#xD;
&#xD;
          -  Consent not obtainable as per the model approved for the specific trial site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Bestle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology and Intensive Care medicine Nordsjællands hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sine Wichmann, MD</last_name>
    <phone>+45 26142620</phone>
    <email>sine.wichmann@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morten Bestle, MD</last_name>
    <phone>+45 41951195</phone>
    <email>morten.bestle@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departmen of Intensive Care</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meike T Behezadi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jørgen Wiis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordsjællands hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Morten Bestle, As professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne C Brøchner, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, Zealand University hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Nebrich, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pia Lawson-Smith, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel I Berezovwicz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikko Järvisalo, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristian Strand, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nordsjaellands Hospital</investigator_affiliation>
    <investigator_full_name>Morten H. Bestle</investigator_full_name>
    <investigator_title>Senior staff specialist and Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fluid overload</keyword>
  <keyword>Fluid removal</keyword>
  <keyword>Oedema</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

